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Mesenchymal stem cells (MSCs) are of interest for use in diverse cellular therapies. Ex vivo expansion of MSCs intended for
transplantation must result in generation of cells that maintain fidelity of critical functions. Previous investigations have identified
genetic and phenotypic alterations of MSCs with in vitro passage, but little is known regarding how culturing influences the ability
of MSCs to repair double strand DNA breaks (DSBs), the most severe of DNA lesions. To investigate the response to DSB stress
with passage in vitro, primary human MSCs were exposed to etoposide (VP16) at various passages with subsequent evaluation
of cellular damage responses and DNA repair. Passage number did not affect susceptibility to VP16 or the incidence and repair
kinetics of DSBs. Nonhomologous end joining (NHEJ) transcripts showed little alteration with VP16 exposure or passage; however,
homologous recombination (HR) transcripts were reduced following VP16 exposure with this decrease amplified as MSCs were
passaged in vitro. Functional evaluations of NHEJ and HR showed that MSCs were unable to activate NHEJ repair following VP16
stress in cells after successive passage. These results indicate that ex vivo expansion of MSCs alters their ability to perform DSB
repair, a necessary function for cells intended for transplantation.

1. Introduction
MSCs are a mesoderm derived stromal population defined
functionally by their ability to differentiate into various cell
types in vitro. Osteoblasts, adipocytes, and chondrocytes
have been shown to arise from MSC precursors under
various culture conditions [1]. MSCs have also been shown
to have immunomodulatory properties, displaying the ability
to suppress adaptive and innate immune responses through
the secretion of anti-inflammatory cytokines [2]. In addition
to these functional characteristics, MSCs are able to persist
in culture, making it possible to alter gene expression of
the cells through various transfection techniques. Such an
approach has been utilized in a rat model of myocardial

infarction to deliver HIF-1𝛼 expressing MSCs to damaged
heart tissue [3]. These cellular attributes have made MSCs an
attractive candidate for the development of stem cell therapies
in humans. MSCs can be acquired from various tissues of
the body including the bone marrow [4]. The injection of
bone marrow derived MSCs is currently undergoing Phase
III clinical trials in the United States for the treatment of
Crohn’s disease and myocardial infarction (clinicaltrial.gov
identifiers NCT00482092 and NCT01394432, resp.). In addition, several preclinical applications have been described in
animal models of disease, such as autoimmune encephalitis,
graft versus host disease, rheumatoid arthritis, type I diabetes,
and inflammatory bowel disease [5].
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The use of MSCs for cellular therapies requires the
ability of ex vivo expansion generating adequate numbers
of cells for treatment. Although there is significant evidence documenting the clinical utility of MSCs, they are
a heterogeneous population of cells that differ based on
the means by which they are acquired and how they are
cultured in vitro [6]. Given their utility, it is important to
understand how they are altered during the necessary ex
vivo expansion prior to patient administration. It has been
shown previously that ex vivo expansion of MSCs results
in alterations in genome stability [7, 8], epigenetics [9, 10],
and functional abilities to differentiate into osteogenic cells
[11, 12]. However, these studies have been performed in
nonstressed conditions, and little has been shown regarding
how the activity of MSCs may be altered once administered
to a patient where they may encounter cellular stresses, such
as DNA damage. Eukaryotes have evolved means to recover
from many types of DNA damage, the most lethal of which
are double strand breaks (DSBs). DSBs are repaired by two
major repair pathways: nonhomologous end joining (NHEJ)
and homologous recombination (HR) [13]. NHEJ involves the
resection of nucleotides from both sides of a DSB, followed
by the binding of Ku70 and Ku80 proteins with DNA-PKcs ,
which recruits DNA ligase IV and initiates ligation of the
break [14]. NHEJ is capable of repairing incompatible ends
regardless of cell cycle status. When a sister chromatid is
present (during S/G2/M phases of cell cycle), HR is capable of
repairing a break by resecting both ends of a break, followed
by insertion of the 3 resected end into the homologous
sequence, thereby using it as a template for repair. Due to the
presence of a homologous sequence, HR is less error-prone
than NHEJ; however, the necessity of a reference template
limits the utilization of HR to S/G2/M phases of cell cycle [15].
To determine how ex vivo expansion alters the response
of MSCs to stress, we utilized etoposide (VP16), a DNA typeII topoisomerase inhibitor that specifically induces DSBs
following DNA replication [16]. DSBs are the most lethal of
DNA lesions, resulting in a larger degree of somatic mutation
or apoptosis than other DNA lesions [17]. To determine how
ex vivo expansion alters the response of MSCs to DSB stress,
we passaged bone marrow derived MSCs in vitro, evaluating
their responses to cellular stress and DSB repair following
VP16 exposure.

2. Materials and Methods
2.1. Human MSC Isolation and Cell Culture. Bone marrow
aspirates were deidentified samples from patients treated at
the West Virginia University Healthcare System. Cells were
cultured in 𝛼-MEM supplemented with 10% fetal bovine
serum (BSA), 2 mM L-glutamine, 100 U/mL penicillin, and
100 𝜇g/mL streptomycin and housed at 37∘ C, 6% CO2 . MSCs
were derived from donors who had no previous exposure to
chemotherapy or irradiation and no history of malignancy.
2.2. Surface Staining of MSCs. Cells were trypsinized and
washed in 1x phosphate buffered saline (PBS). Primary antibodies (1 𝜇g) specific for human CD45, CD44, CD105, and
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CD166 (BD Pharmingen, San Jose, California, United States)
were added and incubated on ice for 20 minutes in PBS/3%
BSA. Cells were washed in PBS/3% BSA and then incubated
with 1 𝜇g donkey anti-mouse-AF488 (BD Pharmingen, San
Jose, California, United States) for 20 minutes on ice. Cells
were then washed in PBS/3% BSA, resuspended in 400 𝜇L
PBS, and immediately analyzed using a FACS Fortessa (BD
Biosciences, Franklin Lakes, New Jersey, United States).
2.3. Differentiation of MSCs. To induce osteogenic differentiation in human MSC cultures, cells were plated at 90% confluence then cultured in Stempro Osteogenesis Differentiation
Kit Medium (Life Technologies, Carlsbad, California, United
States) for 21 days. Differentiation medium was changed
every 3 days. To induce adipogenic differentiation, cells
were treated similarly only cultured in Stempro Adipogenesis
Differentiation Kit Medium (Life Technologies, Carlsbad,
California, United States) for 10 days. Differentiated cells were
compared to undifferentiated controls, cultured in normal
MSC medium (see Section 2.1).
2.4. Alizarin Red and Oil Red Staining. Human MSCs were
fixed in 4% paraformaldehyde (Sigma, St. Louis, Missouri,
United States) for 4 hours prior to staining. Alizarin red
and oil red staining were performed as described previously
[18, 19]. Cells were washed in deionized water and imaged
immediately at 100x magnification using a Leica DMIL LED
Inverted Microscope and Leica DFC 295 Digital Microscope
Color Camera (Leica Microsystems, Wetzlar, Germany).
2.5. Presto Blue Viability Assay. Human MSCs were plated
at 90% confluence in 96-well plates, each plate containing
unexposed and VP16 exposed cells, with 5 wells per group.
Cells were exposed to 25 𝜇M VP16 or medium only control
for 24 hours. After incubation, cells were washed 3 times and
allowed for 0, 6, or 48 hours to recover. At each time point,
viability was assessed using Presto Blue Cell Viability Reagent
(Life Technologies, Carlsbad, California, United States) as
per manufacturer’s recommendation. Well ODs were blanked
to wells containing medium and Presto Blue Cell Viability
Reagent alone prior to analysis.
2.6. Etoposide Exposure. VP16 (Bristol-Myers Squibb, New
York, New York, United States) was stored in 33.98 mM
aliquots at −20∘ C and diluted to 25 𝜇M immediately prior to
use in MSC medium (see Section 2.1).
2.7. Fluorescent Microscopy. Cells were plated at 90% confluence on glass coverslips in 24-well plates and then exposed to
25 𝜇M VP16 or medium alone for 24 hours. Following incubation, cells were washed three times and then allowed for 0,
6, or 48 hours to recover. At each recovery time, coverslips
were washed with 1x PBS and then fixed for 6 hours in 4%
paraformaldehyde. Following fixing, cells were permeabilized
with 0.5% Triton X-100 and then treated with Image-iT FX
Signal Enhancer (Life Technologies, Carlsbad, California,
United States) for 20 minutes. Following a 20-minute block
with 5% BSA, cells were incubated with 𝛾-H2AX antibody
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(1 : 400 Dilution, Millipore, Billerica, Massachusetts, United
States) overnight at 4∘ C. Following incubation, the cells were
washed in 1x PBS and then incubated for 1 hour in Goat
anti-Rabbit-FITC secondary antibody (1 : 200, Cell Signaling,
Danvers, Massachusetts, United States) prior to mounting on
coverslips with ProLong Gold Antifade Reagent with DAPI
(Life Technologies, Carlsbad, California, United States). Antibodies were diluted in 5% BSA. Following staining, cells
were imaged on a Zeiss LSM 510 Laser Scanning Confocal
Microscope (Zeiss, Jena, Germany). 𝛾-H2AX was quantitated
as cells expressing 10 or more foci or manually counted at
the 6-hour recovery time point to determine 𝛾-H2AX on a
per-cell basis. The 6-hour recovery time point was utilized
for counting because foci were too abundant at 0 hours of
recovery to discern individual foci.
2.8. RNA Isolation and qPCR. RNA was isolated using Qiagen
RNeasy Minikit (Qiagen, Valencia, California, United States)
and stored at −80∘ C prior to qPCR. RNA stock solutions
were diluted to 50 ng/11 𝜇L concentration prior to qPCR
analysis. One-step qPCR reactions were performed using
QuantiTect SYBR Green RT-PCR Kit (Qiagen, Valencia,
California, United States) and a 7500 Applied Biosystems
Thermalcycler (Applied Biosystems, Foster City, California,
United States). Primers sequences are indicated in Supplementary Table 1 in Supplementary Material available online
at http://dx.doi.org/10.1155/2016/8270464. PCR data were
analyzed using the ΔΔCt method [20].
2.9. Cell Cycle Analysis. Following trypsinization, cells were
fixed in 70% ethanol for 24 hours prior to cell cycle analysis.
Once fixed, cells were washed in 1x PBS and then stained
with propidium iodide staining solution (0.1% Triton X-100,
0.2 mg/mL RNaseA, and 0.02 mg/mL propidium iodide) for
30 minutes at room temperature. Cells were then resuspended in 1x PBS and ran on Beckman FACS Calibur
(BD Biosciences, Franklin Lakes, New Jersey, United States).
Analysis of cell cycle data was performed using FCS Express
4 Software (De Novo Software, Glendale, California, United
States).
2.10. Western Blot Analysis. Protein was isolated from whole
cell lysates prior to Western analysis using reducing conditions. Blots were probed using Rad51 (Cell Signaling, Danvers, Massachusetts, United States) and XRCC3 (Novus Biologicals, Littleton, Colorado, United States) antibodies and
anti-rabbit-HRP (Cell Signaling, Danvers, Massachusetts,
United States). Immobilon Western ECL reagents (EMD
Millipore, Billerica, Massachusetts, United States) were used
to develop membranes.
2.11. NHEJ and HR Reporter Assays. Functional contributions of NHEJ and HR to DSB repair were evaluated
using reporter assays developed and kindly provided by
Dr. Vera Gorbunova (University of Rochester, Rochester,
NY). NHEJ and HR constructs are designed with a Pem1
adenoviral intron interrupting the reading frame of GFP.
The Pem1 intron is flanked by I-SceI restriction sites that,

3
when repaired by NHEJ or HR, restores the reading frame
of GFP, resulting in expression which can be quantitated
by flow cytometry along with a DsRed loading control to
evaluate transfection efficiency. The total %GFP+ /%DsRed+
gives the repair efficiency, a number that quantitatively
reflects the degree to which MSCs have utilized NHEJ or
HR to repair the reporter plasmid [21]. Cells were exposed
to 25 𝜇M VP16 for 24 hours prior to isolation of cells for
analysis as previously described [22]. Cells were nucleofected
using an Amaxa Nucleofector (Lonza, Basel, Switzerland),
program U-23. Cells were nucleofected with 2 𝜇g HR or 0.5 𝜇g
NHEJ constructs and 0.5 𝜇g DsRed loading control. Prior
to nucleofection, NHEJ and HR constructs were linearized
with I-SceI (New England Biolabs, Ipswich, Massachusetts,
United States) as previously described [22]. 10 𝜇g of EGFP-N1
or DsRed-Express-DR (Clontech, Mountain View, California,
United States) plasmids were included as positive controls.
Following nucleofection, cells were cultured for 72 hours and
then evaluated for GFP and DsRed expression using FACS
Fortessa flow cytometer.
2.12. Statistical Analysis. For Presto Blue viability analysis, two-way Student’s 𝑡-tests were performed comparing
untreated to treated cells at each recovery time. 𝛾-H2AX
quantitation and NHEJ/HR reporter assay data were evaluated by One-Way ANOVA with Holm-Sidak Post Hoc test.
𝛾-H2AX data in Supplemental Figure 2 were evaluated using
the Kruskal-Wallis test. Statistical significance was defined as
𝑝 value ≤ 0.05 using SigmaPlot Version 11 (Systat Software
Inc., San Jose, California, United States). Experiments have
been repeated at least twice using cell lines derived from
different patients and three times for surface marker phenotyping, Presto Blue, cell cycle analysis, 𝛾-H2AX microscopy,
and NHEJ/HR qPCR experiments. Error bars in all figures
indicate standard error.

3. Results
3.1. MSC Characteristics with Passage Ex Vivo. Consistent
with an MSC phenotype [23, 24], bone marrow derived
MSCs showed an ability to perform both osteogenic and
adipogenic differentiation (Figures 1(a) and 1(b)) and were
CD45− CD44+ CD105+ CD166+ (Figure 1(c)). The adipogenic
differentiation potential of MSCs appeared consistent up
to passage 12 (Figure 1(b)). Previously, MSCs have been
shown to display reduced osteogenic differentiation potential
following prolonged passage in vitro [11, 12]. In addition,
extensive culturing of MSCs has been shown to reduce the
proportion of cells in S phase [25]. Consistent with these
observations, we found that the osteogenic differentiation
potential of passage 12 MSCs was reduced relative to less
passaged cells (Figure 1(a)). The cell cycle distribution of
MSCs was similar in passage 6 to passage 10 cells; however,
the proportion of cells in S phase was reduced at passage
12 (Figure 3(a), untreated). These results indicate that our
cells were characteristic of MSCs and displayed a functional
phenotype consistent with extended passage ex vivo by
passage 12.
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Figure 1: Differentiation and surface phenotype of bone marrow derived mesenchymal stem cells (MSCs). (a) Osteogenic and (b) adipogenic
differentiation at various passages evaluated by alizarin red and oil red staining, respectively. (c) Flow cytometry detecting surface expression
of MSC surface markers. Black lines represent isotype controls; red lines represent indicated surface markers.

In addition to differentiating into various mesenchymal
lineages, MSCs functionally contribute to the regulation of
the differentiation and proliferation of hematopoietic cells
[26]. MSCs also provide chemotactic gradients that enable
hematopoietic cell homing to the bone marrow [27], a process
that we have previously shown to be negatively affected by
chemotherapy exposure of bone marrow stromal cells and
osteoblasts [28, 29]. A preliminary set of experiments did
not provide evidence for passage related alterations of the
ability of VP16 exposed MSCs to regulate the proliferation
or chemotaxis of a stromal cell dependent murine pro-B
cell clone or the differentiation of normal human CD34+
hematopoietic progenitor cells (data not shown).

3.2. Sublethal Concentrations of VP16 Induce Cell Cycle Arrest
in MSCs Regardless of Passage. To determine how MSCs
respond to stress with successive passage in vitro, cells were
exposed to VP16 for 24 hours at 90% confluence, then washed
three times in complete medium, and allowed for 0, 6, or
48 hours to recover prior to analyses. Cells were exposed
to VP16 at 90% confluence due to the cell cycle specific
nature of both VP16 and HR mediated repair of DSBs.
VP16 specifically induces DSBs during mitotic events [16];
therefore subconfluent cells were used in our model. 25 𝜇M
VP16 was utilized because it was the highest concentration
of VP16 that did not result in overt cell death up to 48
hours of recovery time (Figure 2 and data not shown) and
therefore represented sublethal stress in our model. Exposure
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Figure 2: Viability of MSCs with passage following 24 hours of
etoposide (VP16) exposure. MSCs at various passages were exposed
to 25 𝜇M VP16 for 24 hours and then allowed for 0, 6, or 48 hours to
recover in fresh medium before evaluation of viability by Presto Blue
viability reagent. Values are reported relative to untreated controls.
∗ indicates a significant decrease in viability relative to untreated
control, Student’s 𝑡-test; 𝑝-value < 0.05.

of MSCs to VP16 resulted in occasional statistically significant
drops in viability; however no passage related trends were
present. Consistent with the absence of passage related
trends in the viability of MSCs following VP16 exposure,
the abundances of proapoptotic (PUMA and NOXA) and
antiapoptotic (BCL-XL and BCL-2) transcripts were similar
with passage following VP16 stress (Supplementary Figure 1).
These results suggest that MSCs do not display alterations in
susceptibility to VP16 up to passage 12 in vitro.
Exposure of MSCs to sublethal concentrations of VP16
resulted in a transcriptional induction of p21 which was
similar among all passages (Figure 3(b)). p21 was elevated
approximately 4- to 6-fold after 24 hours of exposure to
VP16 and remained elevated following 48 hours of recovery.
Consistent with increased p21, VP16 exposure resulted in
a reduction in the proportion of cells in S/G2/M phase of
cell cycle (Figure 3(a)). The transcriptional abundances of
p16 and p53 were gradually decreased following exposure to
VP16 (Figure 3(b)), suggesting that the observed G1 arrest
was due to the earlier and relatively more robust induction of
p21 following VP16 exposure. These results suggest that VP16
induces cell cycle arrest at all passages in ex vivo expanded
MSCs.
3.3. Ex Vivo Passage of MSCs Does Not Alter Incidence or
Repair Kinetics of DSBs following VP16 Exposure. To visualize
DSBs in MSCs following VP16 exposure, immunofluorescent
staining of 𝛾-H2AX was utilized, as described previously
[30]. MSCs displayed a large number of DSBs following 24
hours of exposure to VP16 (Figure 4(a)). After 48 hours of
recovery time, the abundance of DSBs decreased, resulting
in less than 20% of cells displaying 10 or more 𝛾-H2AX foci

(Figures 4(a) and 4(b)). The proportion of cells with 10 or
more 𝛾-H2AX foci did not appear influenced by passage
number at any time point, suggesting that the repair kinetics
of DSBs are similar among MSCs of all passages. To more
accurately quantitate the number of DSBs on a per-cell basis,
𝛾-H2AX foci were manually counted at 6 hours of recovery,
showing no significant change with passage (Figure 4(c)).
Based on these findings, it appears that the incidence and
repair kinetics of DSBs following VP16 induced stress do not
change with passage in vitro.
3.4. Alterations in NHEJ and HR Mediated Repair of DSBs with
Passage and VP16 Exposure. To determine which repair pathways MSCs utilize to repair DSBs, as well as whether pathway
dependence is altered by in vitro passage, transcriptional
responses of NHEJ and HR associated genes were evaluated
in our model. KU70, KU80, and DNA-PK were used to
evaluate NHEJ, while XRCC2, XRCC3, and RAD51 were
used to evaluate HR. Following VP16 stress, NHEJ associated
transcripts remained relatively unaltered (less than 2-fold
changes from baseline) and displayed no passage associated
trends in abundance (Figure 5(a)). However, VP16 exposure
reduced the abundance of HR associated transcripts, and this
reduction was augmented with passage in vitro (Figure 5(b)).
The decreased presence of HR transcripts following VP16 is
consistent with the induction of cell cycle arrest displayed
by our cells, given that HR can only be performed during
S/G2 phases of the cell cycle [15]. The augmented decrease
in HR associated transcripts with passage (following VP16
exposure) does not appear to be due to the reduced cyclingstatus of MSCs with extended passage, as the HR transcript
decreases are present immediately following passage 6 while
extended culture associated decreases in S/G2/M are not
present until passage 12 (Figure 3(a), untreated). Consistent
with qPCR results, protein abundance of Rad51 was decreased
following VP16 stress at all passages. However, the abundance
of XRCC3 was unaltered (Figure 5(c)). These data suggest that
the reliance of MSCs on HR is reduced following VP16 stress
and that there is altered double strand DNA repair pathway
utilization with in vitro passaging of MSCs that precedes
the changes in cell cycle distribution associated with in vitro
culture.
To evaluate the functional contribution of NHEJ and HR
to DSB repair in MSCs following VP16 exposure, NHEJ and
HR plasmid reporter assays were utilized. NHEJ and HR
reporter assays serve as a means to quantitatively evaluate the
functional ability of cells to perform NHEJ or HR, reported as
repair efficiency [22]. The average repair efficiency of NHEJ in
untreated passage 6 cells was approximately 0.165, compared
to 0.03 for HR, indicating that NHEJ is the predominant
repair pathway of DSBs in MSCs, consistent with other cell
types of the body [31] (Figure 5(d)). The repair efficiency of
NHEJ in untreated cells remained consistent with passage of
MSCs; however, the repair efficiency of HR was significantly
reduced by passage 12 (Figure 5(d)). Coincident with reduced
HR repair efficiency, untreated cells displayed reduced Rad51
protein abundance with passage (Figure 5(e)). Following
VP16 exposure, passage 6 and 9 cells displayed significantly
elevated repair efficiency for NHEJ, while the efficiency of
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Figure 3: Effects of VP16 on cell cycle distribution and cell cycle inhibitor transcript abundance with passage. (a) Cell cycle distribution of
MSCs at various passages exposed to 25 𝜇M VP16 or medium only control for 24 hours. (b) qPCR evaluation of cell cycle inhibitor mRNA
expression following exposure of MSCs to 25 𝜇M VP16 for 24 hours followed by 0, 6, or 48 hours of recovery in fresh medium. Values are
indicated as fold change relative to untreated control.

HR was significantly reduced (Figure 5(d)). Interestingly,
passage 12 cells did not display significant changes in repair
efficiency following VP16 exposure relative to untreated
controls (Figure 5(d)). These results indicate that NHEJ is
primarily used to repair DSBs in MSCs and that NHEJ is
increased in the context of VP16 stress while HR is decreased.
However, once cells have undergone extended passage in
vitro, MSCs are less able to utilize HR for repair, and DSB
repair using NHEJ is not functionally increased following
VP16 exposure. These data suggest that prolonged passage of
MSCs in vitro can alter the ability to utilize NHEJ and HR
following exposure to sublethal VP16 induced stress.

4. Discussion
The plasticity and immunomodulatory potential of MSCs
have attracted attention regarding their application in cellular therapies for numerous diseases. The ability of MSCs

to expand in vitro has further increased enthusiasm for
clinical application, circumventing potential problems with
the acquisition of sufficient cell numbers for transplantation.
In addition, MSCs can be acquired from various tissues
of the body [4], making it possible to utilize cells from a
patient autologously, nullifying the risks of graft versus host
disease. The ability of MSCs to expand ex vivo is beneficial
towards their use clinically, highlighting the necessity of
understanding how cells are changed during culture in vitro.
In vitro culture has been shown to epigenetically regulate
gene expression in MSCs. Passage related increases in HDAC
activity correlate with increased expression of HDAC4,
HDAC5, and HDAC6, resulting in reduced H3 and H4
acetylation and reduced OCT4 expression [9]. Another study
documented passage associated alterations in methylation at
specific CpG sites, many of which regulate differentiation
associated genes including RUNX3 [10], which has been
implicated in osteogenesis [32]. In addition to alterations
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Figure 4: DNA double strand break incidence and repair kinetics in MSCs exposed to 25 𝜇M VP16. (a) Representative 𝛾-H2AX staining
(yellow) of Passage 6 MSCs exposed to VP16 for 24 hours followed by 0, 6, or 48 hours of recovery in fresh medium. 𝛾-H2AX (Yellow)
displays nuclear colocalization with DAPI (blue). (b) Percentage of MSCs displaying 10 or greater 𝛾-H2AX foci at each time point at various
passages. (c) Average number of 𝛾-H2AX foci per cell at 6 hours of recovery time for passages 6 through 12. “NS” indicates no significant
difference between any passage by One-Way ANOVA with Holm-Sidak Post Hoc test; 𝑝-value > 0.05.

in gene regulation, in vitro passaging of MSCs reduces
osteogenic differentiation capacity [11, 12]. Consistent with
these observations, we showed a reduced ability of passage
12 MSCs to differentiate under osteogenic conditions relative
to lower passages (Figure 1(a)), indicating that our cells had
been cultured sufficiently to elicit changes in MSC function.
However, we did not observe reduced adipogenic differentiation potential up to passage 12 (Figure 1(b)) which defined
the endpoint of our model. These studies display important
cellular characteristics that are altered with ex vivo passage,
but little has been done to address how passaging alters
their response to stresses resulting in DSB formation. Part of
the reason DSBs are the most damaging of DNA lesions is

the result of increased likelihood of erroneous repair, especially following NHEJ [33]. Erroneous repair is associated
with increased cellular transformation, a phenomenon that
has been documented with in vitro passage of MSCs [7, 8],
alluding to the importance of maintaining not only survival,
but genomic integrity of ex vivo expanded MSCs. The specific
induction of DSBs by VP16 enabled us to specifically evaluate
MSC responses regarding DSB repair. Although any type of
DNA lesion can be harmful to a cell, DSBs are considered the
most serious and potentially mutagenic [13], hence their focus
in our investigation.
To model cellular stress as a consequence of DSB presence, we utilized sublethal concentrations of VP16 that
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Figure 5: Nonhomologous end joining (NHEJ) and homologous recombination (HR) transcriptional, protein, and functional repair
responses to 25 𝜇M VP16 with passage. qPCR evaluation of (a) NHEJ and (b) HR associated mRNA expression following exposure of MSCs
to VP16 for 24 hours followed by 0 or 48 hours of recovery in fresh medium. Fold changes are indicated relative to untreated controls. (c)
Western analysis of Rad51 and XRCC3 after VP16 exposure with passage. “Untr” indicates untreated cells. “0,” “6,” or “48” indicates recovery
time (in hours) following 24 hours of exposure to 25uM VP16. (d) NHEJ and HR plasmid reporter assays for Passage 6, 9, and 12 MSCs
exposed to VP16 or medium only control for 24 hours. (e) Western analysis of Rad51 in untreated MSCs with passage. # indicates significant
change relative to untreated control; ∗ represents significant change relative to indicated group, One-Way ANOVA with Holm-Sidak Post
Hoc test; 𝑝-value < 0.05.
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displayed no passage associated changes in the susceptibility
of MSCs to VP16 induced cell death (Figure 2). VP16 did not
result in overt death but did increase p21 mRNA and elicited
a reduction in the proportion of cells in S/G2/M phases of cell
cycle indicating cell cycle arrest at all passages (Figures 3(a)
and 3(b)). Although capable of initiating G1 arrest following
cellular stress [34], we found p16 and p53 transcripts to be
reduced by 6 hours of recovery time (Figure 3(b)). The earlier
and more robust presence of p21 may have chiefly contributed
to the induction of cell cycle arrest, consistent with previous
observations in stressed MSCs [35]. These observations show
that MSCs display signs of cellular stress in our model of VP16
exposure in a manner that is sublethal. The absence of cellular
death in our model enabled us to evaluate the incidence,
repair kinetics, and cellular repair pathways of DSBs within
MSCs with passage.
Of the numerous types of DNA lesions, VP16 specifically
generates DSBs [36]. Within minutes following the formation
of a DSB within the nucleus, various kinases (including DNAPK, ATM, and ATR) detect the presence of the break and
phosphorylate histone 2A moieties. Phosphorylated histone
2A (𝛾-H2AX) present as nuclear puncta corresponding to
an individual DSB that can be visualized by immunofluorescence [30]. When evaluating 𝛾-H2AX foci at each time point
after VP16 exposure, changes were not observed between
passages (Figure 4(b)) suggesting that the rate by which MSCs
repair VP16 induced DNA damage is not affected by passage
in vitro. Notably, less than 20% of the cells contained 10 or
more 𝛾-H2AX foci by 48 hours of recovery (Figure 4(b)).
The greatly reduced presence of DSBs following 48 hours of
recovery time suggests that MSCs are capable of recovering
from 25 𝜇M VP16 exposure, consistent with the sublethal
nature of the model. These results indicate that the incidence
and repair kinetics of DSBs following VP16 exposure were
similar across passage number in vitro.
The resolution of DSBs following 48 hours of recovery
from VP16 exposure suggests the intact presence of double
strand DNA repair pathways within MSCs for all passages
observed. DSBs are repaired through two major pathways:
NHEJ and HR [15]. To elucidate the contribution of these
pathways to repair with passage in the context of VP16 stress,
transcriptional responses of a panel of NHEJ and HR genes
were evaluated. Although NHEJ transcripts displayed little
change, HR associated transcripts were reduced with VP16
exposure (Figures 5(a) and 5(b)). Evaluations of Rad51 and
XRCC3 protein showed that although XRCC3 was unaltered
by passage or VP16 exposure, Rad51 was reduced by VP16,
consistent with qPCR results (Figure 5(c)). Although these
results served as evidence for VP16 exposure and passage
playing a role in the means by which MSCs repair DNA,
qPCR cannot describe which pathways are being utilized
functionally by MSCs and to what extent. To functionally
and quantitatively evaluate the contribution of NHEJ and
HR to DSB repair in VP16 stressed MSCs, plasmid based
reporter assays were utilized. We showed that, at baseline,
NHEJ was the primary DSB repair pathway utilized by MSCs
(Figure 5(d)), consistent with most cell types of the body [17].
In lower passage cells (passages 6 and 9), NHEJ is increased
while HR is decreased following VP16 stress (Figure 5(d)).
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However, in passage 12 cells, there was reduced presence of
HR at baseline, possibly due to the reduced abundance of
Rad51 (Figure 5(e)), and VP16 induced increases or decreases
in NHEJ or HR (resp.) were not present (Figure 5(d)).
These results suggested that, in lower passage cells, NHEJ
is increased to repair DNA damage while HR is decreased;
however, later passage cells are unable to increase NHEJ
mediated repair following VP16 stress. Passaging and irradiation of fibroblasts have been shown to alter the abundance
and localization of Ku70/80 [37], possibly playing a role
in the inability of late passage MSCs to increase NHEJ
efficiency following VP16 stress (Figure 5(d)). Quantitation
of 𝛾-H2AX foci in untreated cells with passage did not show
significant changes (Supplementary Figure 2), suggesting that
the genomic integrity of untreated cells is not affected by
defects in HR repair with ex vivo expansion. In addition,
the inability of passage 12 MSCs to increase NHEJ following
VP16 exposure did not result in alterations of DSB presence
or viability when compared to lesser passaged MSCs (Figures
2 and 4). These results are most likely due to the sublethal
nature of our model. It is possible that, at higher concentrations of VP16, the consequences of less efficient DNA repair
would affect the presence or repair kinetics of DSBs. However,
due to the nature of our assays only evaluating living cells,
the phenomenon would likely not be detected (a problem
evaded by our use of nonlethal concentrations of VP16).
Nevertheless, our results suggest a defective ability of MSCs to
increase NHEJ, their primary repair pathway of DSBs, in the
context of VP16 stress following successive passage in vitro.
Our results showing reduction in the efficiency of HR
following in vitro culture of MSCs are consistent with previous findings in fibroblasts [38]. However, when Seluanov
et al. evaluated NHEJ efficiency in fibroblasts with successive
passaging (up to 70 population doublings), NHEJ efficiency
was found to be decreased [39]. Our results with normal
primary human MSCs did not show significant changes in
NHEJ efficiency in untreated cells regardless of passage,
possibly due to the fact that our cells were passaged to a
lesser extent (passage 12). The results presented in this report
contribute unique information by evaluating passage related
changes in DSB repair in the context of cellular stress, a
common circumstance that will be encountered when the
ability to repair DNA is crucial. In addition, DSB repair being
quantitatively evaluated in MSCs adds to our understanding
of the characteristics of these clinically valuable stem cells.
Given recent observations that NHEJ utilization varies by
tissue type in vivo [31], the specific evaluation of DNA repair
in human primary marrow derived MSCs is relevant to
developing optimal models to expand cells ex vivo for diverse
cellular therapies.

5. Conclusions
In conclusion, we have determined that extended culture of
human primary bone marrow derived MSCs results in an
inability to functionally increase NHEJ when encountering
sublethal VP16 stress and reduced utilization of HR in the
absence of stress. Given the necessity of ex vivo expansion
of MSCs for use in cellular therapies, these results serve as
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a guideline for improving strategies to sufficiently expand
MSCs without inducing culture associated alterations that
could have negative effects on the ability of the cells to persist
following transplantation. Both the inability of MSCs to
increase NHEJ following VP16 stress and reduced osteogenic
differentiation capacity were detected at passage 12 (Figures
5(d) and 1(a), resp.). Although we do not propose that these
events are directly related, they highlight the possibility of
utilizing a biomarker to determine when ex vivo expanded
MSCs display impaired DSB repair abilities in the context
of stress. The discovery of such biomarkers would enable
screening for DNA repair deficiencies without the time,
cell, and labor intensive requirements of performing plasmid
based DSB repair assays prior to utilization of ex vivo
expanded MSCs for cellular therapy.
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